Zenagamtide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Zenagamtide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
24
Registered trials
5
Result records
10
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Zenagamtide can convert its Peptide Hormone profile and AMYR x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Zenagamtide (query alias: amycretin) |
|---|---|
| Modality / target | Peptide Hormone; AMYR x GLP-1R; AMYR agonists, GLP-1R agonists |
| Highest global status | Phase 3 |
| Originator | Novo Nordisk A/S |
| Active developers | Novo Nordisk A/S, Novo Nordisk China Pharmaceuticals Co. Ltd., Novo Nordisk Pharmaceuticals Pty Ltd. |
The MCP disease footprint includes Heart Failure, Sleep Apnea, Obstructive, Weight Loss. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07668414 | Phase 3 | Not yet recruiting | 650 | Relative change in body weight |
| NCT07668401 | Phase 3 | Not yet recruiting | 400 | Relative change in body weight |
| NCT07571005 | Phase 3 | Recruiting | 300 | Relative change in body weight |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
Phase 2; n=448; evaluation: Positive. Reported fields: HbA1c(change fr baseline at Week 36) = -0.4 % Met; HbA1c(change fr baseline at Week 36) = up to -1.5 % Met; HbA1c(change fr baseline at Week 36) = -1.8 % Met
2002-LB: Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist—Results of a Phase 1b/2a Clinical Trial
Phase 1/2; n=101; evaluation: Positive. Reported fields: Body weight(Parts B-E) = -1.1 % ; Body weight(Parts B-E) = -24.3 %
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Phase 1/2; n=125; evaluation: Positive. Reported fields: AE = The most common adverse events with amycretin were gastrointestinal and the vast majority were mild to moderate in severity. ; AE = The most common adverse events with amycretin were gastrointestinal and the vast majority were mild to moderate in severity. ; AE = The most common adverse events with amycretin were gastrointestinal and the vast majority were mild to moderate in severity.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Zenagamtide addresses Heart Failure, Sleep Apnea, Obstructive, Weight Loss. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Peptide Hormone—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 10 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: AMYR x GLP-1R records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-09-22 | Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama | Phase 1/2 | US$7,600.0M upfront; US$2,400.0M milestones; US$10,000.0M stated total |
| 2025-03-12 | Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity | Phase 2 | US$1,650.0M upfront; US$3,600.0M milestones; US$5,300.0M stated total |
| 2025-03-03 | AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity | Phase 1 | US$350.0M upfront; US$1,875.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
